You are here

HIV Vaccine Research

MHRP is dedicated to developing a safe and globally effective HIV vaccine to protect our Armed Forces wherever they may be deployed. In 2009, MHRP announced findings from its landmark “Thai Study,” RV144, the first clinical trial to show a vaccine regimen was safe and modestly effective in preventing HIV infection. 

MHRP continues to pursue several vaccine strategies in the U.S., East Africa, and Thailand. In addition to building on the success of RV144, MHRP is testing a next-generation MVA vaccine candidate, producing a GP145 vaccine and developing a novel combination HIV-heroin vaccine.

MHRP researchers are also developing and testing novel vaccine strategies, including new adjuvants and improved protein constructs aimed at subtype B, which is common in the Americas, West and Central Europe, Australia, South America and Thailand. New clinical trial sites and partnerships are in development for future HIV vaccine studies in Germany.